Multitype Quantum Well Semiconductor Membrane External-Cavity Surface-Emitting Lasers for Widely Tunable Continuous Wave Operation.

Membrane external-cavity surface-emitting lasers (MECSELs) represent a cutting-edge approach in pushing the performance boundaries of vertically emitting semiconductor lasers. The fundamental concept of employing an extremely thin gain membrane, spanning from hundreds of nanometers to a few micrometers in thickness and sandwiched between transparent heat spreaders, introduces novel opportunities through uniform double-sided optical pumping and enhanced heat dissipation from the active region. Additionally, these advantages of MECSELs facilitate more intricate band gap engineering possibilities for the active region by integrating multiple types of quantum wells (QWs) into a single laser gain structure.

Symptomatic osteonecrosis in children treated for Hodgkin lymphoma: A population-based study in Sweden, Finland, and Denmark.

Background: Osteonecrosis (ON) is a potentially disabling skeletal complication of cancer treatment. Although symptomatic osteonecrosis (sON) is well-known in acute lymphoblastic leukemia (ALL), with an incidence around 6%, studies on sON in pediatric Hodgkin lymphoma (HL) are scarce. The aim of this study was to examine the incidence, risk factors, and outcome of sON in children treated for HL.

Radiological follow-up of osteonecrosis lesions in children and adolescents with Hodgkin lymphoma.

Osteonecrosis (ON) is a common complication of glucocorticoid-based Hodgkin lymphoma (HL) treatment, but the natural evolution and prognosis of ON lesions remain poorly understood. We describe the radiological evolution of ON lesions identified in a Nordic population-based cohort of paediatric HL patients. Magnetic resonance images of suspected ON lesions were centrally reviewed to confirm ON diagnosis and grade the ON lesions according to the Niinimäki classification.

Global Hemostatic Methods to Tailor Treatment With Bypassing Agents in Hemophilia A With Inhibitors- A Single-Center, Pilot Study.

For patients with hemophilia A and high-titer inhibitors treated with bypassing agents there are no reliable methods to assess treatment effect. We investigated the utility of global hemostatic methods in assessing treatment with bypassing agents (rFVIIa or activated prothrombin complex [aPCC]). All patients with hemophilia A and inhibitors followed at the Coagulation Unit or the Pediatric Coagulation Unit at Karolinska University Hospital aged 6 years and above were eligible for this noninterventional study.